Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer

finance.yahoo.com/news/pelthos-acquires-us-rights-xepi-103132619.html

Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera and Ferrer Internacional.
The topical cream is indicated to treat impetigo, a bacterial skin infection caused by Staphylococcus aureus or…

This story appeared on finance.yahoo.com, 2025-11-10 10:31:32.
The Entire Business World on a Single Page. Free to Use →